TL;DR
This paper presents a novel strategy to combat pulmonary fibrosis by engineering mesenchymal stem cells (MSCs) to enhance their ability to transfer healthy mitochondria to damaged lung cells. By treating MSCs with pioglitazone and iron oxide nanoparticles, the researchers created "high-powered" MSCs that efficiently deliver mitochondria, restoring cellular function and significantly mitigating fibrosis in both mouse models and humanized lung spheroids.
What Problem Does This Paper Address?
Pulmonary fibrosis (PF) is a debilitating disease characterized by the scarring of lung tissue, leading to impaired lung function. A promising therapeutic avenue is mitochondrial replenishment therapy (MRT), which aims to replace damaged mitochondria in diseased cells with healthy ones. However, a major hurdle for MRT is the inefficient delivery of sufficient functional mitochondria to the target cells. Existing methods often struggle with selectivity and the rapid loss of mitochondrial activity in the extracellular environment. This paper tackles the challenge of improving the efficiency and specificity of mitochondrial delivery for therapeutic applications in PF.
Methods
The core of this research lies in engineering mesenchymal stem cells (MSCs) to become more effective mitochondrial donors. The strategy involves a two-pronged approach:
- Promoting Mitochondrial Biogenesis: MSCs were treated with pioglitazone (Pg), a drug known to activate the PGC-1α/NRF1/TFAM pathway. This pathway is crucial for increasing mitochondrial production within the cells, effectively creating "high-powered" MSCs with a larger mitochondrial reserve.
- Facilitating Mitochondrial Transfer: To enhance the actual transfer of these mitochondria to injured lung cells, the MSCs were further engineered using iron oxide nanoparticles (IONPs). This approach, building on previous work by the authors, leverages IONPs to upregulate connexin 43 (Cx43) expression, which is believed to facilitate the formation of gap junctions necessary for mitochondrial transfer.
The combination of these two treatments resulted in "Pg-Fe-hMSC" – MSCs engineered for both increased mitochondrial production and enhanced transfer capabilities. The researchers then evaluated the therapeutic efficacy of these engineered MSCs in various models, including:
- In vitro studies: Assessing mitochondrial transfer rates to bleomycin (BLM)-injured lung cells (TC-1), measuring cellular function (ATP levels, ROS production, mitochondrial membrane potential), and evaluating cell viability.
- Mouse PF model: Inducing PF in mice using BLM and then treating them with different MSC variants to assess fibrotic progression via micro-CT, histology (H&E and Masson's trichrome staining), collagen deposition, and levels of fibrotic markers (MMP9, TGF-β, hydroxyproline).
- Humanized fibrotic models: Using primary human lung epithelial cells (hLECs) and a 3D multicellular human lung spheroid model to evaluate the therapeutic potential in more clinically relevant systems.
Datasets
The study utilized several cell lines and biological samples:
- Human mesenchymal stem cells (hMSCs): Derived from the placenta, used as the primary cell for engineering.
- Mouse alveolar epithelial cells (TC-1): Used as a model for injured lung cells in vitro.
- Human lung epithelial cells (hLECs): Isolated from discarded lung tissues for in vitro studies.
- Human bronchial epithelial cells (BEAS-2B) and human lung fibroblasts (Hs888Lu): Used to construct the 3D multicellular human lung spheroid model.
- Human umbilical vein endothelial cells (HUVEC) and human normal lung fibroblasts (Hs888Lu): Used to compare mitochondrial transfer rates to different cell types.
- Mouse lung tissues: Collected from a mouse PF model for histological, biochemical, and RNA sequencing analyses.
- Bronchoalveolar lavage fluid (BALF): Collected from mice for assessment of fibrotic markers.
No new benchmarks were introduced; rather, existing models of pulmonary fibrosis and established cell culture techniques were employed.
Key Insights and Ideas
- Synergistic Engineering for Enhanced MRT: The combination of promoting mitochondrial biogenesis (via pioglitazone) and facilitating transfer (via IONPs) in MSCs creates a significantly more potent mitochondrial donor cell than either approach alone. This highlights the importance of addressing both the "supply" and "delivery" aspects of MRT.
- Mitochondrial Biogenesis as a Key Enabler: Increasing the number of mitochondria within donor cells directly correlates with enhanced mitochondrial transfer. This suggests that targeting mitochondrial biogenesis is a viable strategy to boost MRT efficacy.
- Gap Junctions as a Primary Transfer Mechanism: The study provides evidence suggesting that mitochondrial transfer primarily occurs through gap junctions, specifically annular gap junctions, which are influenced by Cx43 expression.
- Reactivation of Mitophagy: Beyond simply replenishing mitochondria, the engineered MSCs appear to reverse the BLM-induced inhibition of mitophagy in injured cells. This suggests a more comprehensive restoration of mitochondrial homeostasis.
- Clinical Relevance in Humanized Models: The successful demonstration of therapeutic effects in both primary human lung cells and 3D lung spheroids significantly strengthens the translational potential of this approach.
Key Results
- Enhanced Mitochondrial Transfer: Pg-Fe-hMSCs achieved a mitochondrial transfer rate of up to ~30%, which was significantly higher than original hMSCs and previous IONP-engineered MSCs. This transfer was sustained for at least 96 hours.
- Mitigation of Fibrosis in Mice: Treatment with Pg-Fe-hMSCs significantly reduced fibrotic progression in a mouse PF model, as evidenced by reduced fibrotic areas, collagen deposition, and levels of MMP9 and TGF-β. The efficacy was comparable to two doses of Pg-Fe-hMSC versus 21 days of Pirfenidone treatment.
- Improved Cellular Function in Injured Cells: In BLM-treated TC-1 cells, Pg-Fe-hMSC treatment restored ATP levels, decreased ROS, and improved mitochondrial membrane potential, leading to increased cell viability.
- Therapeutic Effects in Humanized Models: In primary human lung epithelial cells, Pg-Fe-hMSC treatment reduced ROS, TGF-β secretion, and improved cell viability. In the 3D fibrotic lung spheroid model, Pg-Fe-hMSC also demonstrated superior mitochondrial transfer, reduced ROS and TGF-β, and improved spheroid viability.
- Genetic Evidence of Mitochondrial Restoration: RNA sequencing analysis of mouse lungs treated with Pg-Fe-hMSC revealed upregulation of genes involved in mitochondrial organization, mitophagy, and ATP synthesis, supporting the restoration of mitochondrial homeostasis.
Limitations and Future Work
- Mechanism of Cx43-Facilitated Transfer: While the study implicates gap junctions and Cx43, the precise mechanism of Cx43-facilitated mitochondrial transfer requires further detailed investigation.
- Comparison with Nintedanib: The study did not directly compare the efficacy of Pg-Fe-hMSC with Nintedanib, another FDA-approved drug for PF, although it notes that both drugs share similar efficiency.
- Long-term Safety and Efficacy: While preliminary safety evaluations in mice showed negligible side effects, further comprehensive long-term safety and efficacy studies in larger animal models and eventually human clinical trials are necessary.
- Optimization of Dosing and Delivery: Further research could focus on optimizing the dosing regimen and delivery routes for Pg-Fe-hMSC to maximize therapeutic outcomes.
- Understanding Mitophagy Reversal: The precise molecular mechanisms by which Pg-Fe-hMSC reverses BLM-induced mitophagy inhibition warrant deeper exploration.
Summary updated